BioCrossroads serves as a catalyst for the continued growth of Indiana’s robust life sciences industry. As part of its mission, BioCrossroads has established life sciences focused, return-driven investment funds. BioCrossroads has also been strongly supported by Indiana’s corporate and academic life sciences leadership, and has partnered with these stakeholders in several ways, including investment and enterprise-formation activities. Managed by BioCrossroads, the Funds make investments in early-stage biotechnology, pharmaceutical, medical device, diagnostic, ag-biotech and health information technology products and platforms and will continue to focus on forming promising companies around innovative ideas. In addition to Esanex, portfolio companies include Algaeon, Assembly Biosciences (Nasdaq:ASMB), Apexian Therapeutics, MB2 (purchased by Novo Nordisk, 2015), Diagnotes, Speechvive, Allinaire Therapeutics and Calibrium (purchased by Novo Nordisk, 2015).